Xvivo Perfusion AB (publ)
XVIPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14,944,124 | $8,850,965 | $5,678,197 | $4,171,415 |
| - Cash | $415,521 | $545,788 | $246,545 | $398,696 |
| + Debt | $34,043 | $31,437 | $10,005 | $5,721 |
| Enterprise Value | $14,562,646 | $8,336,614 | $5,441,657 | $3,778,440 |
| Revenue | $822,415 | $597,542 | $415,292 | $258,386 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $616,415 | $445,111 | $296,956 | $188,279 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $110,902 | $172,061 | $39,211 | $39,198 |
| % Margin | 13.5% | 28.8% | 9.4% | 15.2% |
| Net Income | $172,182 | $91,820 | $18,427 | $8,152 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 1.36 | 0.77 | 0.16 | 0.07 |
| % Growth | 76.6% | 381.3% | 128.6% | – |
| Operating Cash Flow | $111,290 | $46,287 | $27,856 | -$12,059 |
| Capital Expenditures | -$70,731 | -$143,936 | -$130,946 | -$94,074 |
| Free Cash Flow | $40,559 | -$97,649 | -$103,090 | -$106,133 |